Clinical Trial Detail

NCT ID NCT03829410
Title Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Trovagene, Inc.
Indications

colon cancer

rectum cancer

Therapies

Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + PCM-075

Age Groups: adult senior

Additional content available in CKB BOOST